Find Aliskiren manufacturers, exporters & distributors on PharmaCompass

PharmaCompass

Synopsis

Related ProductsRelated Products

Synopsis

ACTIVE PHARMA INGREDIENTS

0

CEP/COS

CEP/COS Certifications

0

JDMF

JDMFs Filed

0

KDMF

KDMF

0

VMF

NDC API

API REF. PRICE (USD/KG)

$
$ 0

MARKET PLACE

FINISHED DOSAGE FORMULATIONS

0

Canada

Canada

0

Australia

Australia

0

South Africa

South Africa

0

Listed Dossiers

Listed Dossiers

0 DRUGS IN DEVELOPMENT

FDF DossiersDRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

0

EDQM

0

USP

0

JP

0

Others

PATENTS & EXCLUSIVITIES

0

US Exclusivities

DIGITAL CONTENT

0

Data Compilation #PharmaFlow

0

Stock Recap #PipelineProspector

0

Weekly News Recap #Phispers

GLOBAL SALES INFORMATION

Annual Reports

NA

162 RELATED EXCIPIENT COMPANIES

273EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set
Also known as: 173334-58-2, Tekturna, Aliskiren fumarate, Aliskiren (hemifumarate), Enviage, Riprazo
Molecular Formula
C64H110N6O16
Molecular Weight
1219.6  g/mol
InChI Key
KLRSDBSKUSSCGU-KRQUFFFQSA-N
FDA UNII
C8A0P8G029

Aliskiren
Aliskiren Hemifumarate is an orally active nonpeptide renin inhibitor with antihypertensive activity. Aliskiren selectively binds to the S3 sub-pocket of renin, an enzyme in the renin-angiotensin-aldosterone system (RAAS) that is responsible for converting angiotensinogen to angiotensin I (AT I). By inhibiting the activity of renin, the conversion to AT I is prevented, which in turn prevents the conversion of AT I to AT II. This prevents arterial vasoconstriction by AT II and inhibits the production of aldosterone by AT II. As aldosterone causes re-uptake of sodium and water and eventually an increase in extracellular volume, aliskiren is able to prevent the effects that contribute to an increase in blood pressure.
1 2D Structure

Aliskiren

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
(2S,4S,5S,7S)-5-amino-N-(3-amino-2,2-dimethyl-3-oxopropyl)-4-hydroxy-7-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-8-methyl-2-propan-2-ylnonanamide;(E)-but-2-enedioic acid
2.1.2 InChI
InChI=1S/2C30H53N3O6.C4H4O4/c2*1-19(2)22(14-21-10-11-26(38-8)27(15-21)39-13-9-12-37-7)16-24(31)25(34)17-23(20(3)4)28(35)33-18-30(5,6)29(32)36;5-3(6)1-2-4(7)8/h2*10-11,15,19-20,22-25,34H,9,12-14,16-18,31H2,1-8H3,(H2,32,36)(H,33,35);1-2H,(H,5,6)(H,7,8)/b;;2-1+/t2*22-,23-,24-,25-;/m00./s1
2.1.3 InChI Key
KLRSDBSKUSSCGU-KRQUFFFQSA-N
2.1.4 Canonical SMILES
CC(C)C(CC1=CC(=C(C=C1)OC)OCCCOC)CC(C(CC(C(C)C)C(=O)NCC(C)(C)C(=O)N)O)N.CC(C)C(CC1=CC(=C(C=C1)OC)OCCCOC)CC(C(CC(C(C)C)C(=O)NCC(C)(C)C(=O)N)O)N.C(=CC(=O)O)C(=O)O
2.1.5 Isomeric SMILES
CC(C)[C@@H](CC1=CC(=C(C=C1)OC)OCCCOC)C[C@@H]([C@H](C[C@@H](C(C)C)C(=O)NCC(C)(C)C(=O)N)O)N.CC(C)[C@@H](CC1=CC(=C(C=C1)OC)OCCCOC)C[C@@H]([C@H](C[C@@H](C(C)C)C(=O)NCC(C)(C)C(=O)N)O)N.C(=C/C(=O)O)\C(=O)O
2.2 Other Identifiers
2.2.1 UNII
C8A0P8G029
2.3 Synonyms
2.3.1 MeSH Synonyms

1. 2(s),4(s),5(s),7(s)-n-(2-carbamoyl-2-methylpropyl)-5-amino-4-hydroxy-2,7-diisopropyl-8-(4-methoxy-3-(3-methoxypropoxy)phenyl)octanamid Hemifumarate

2. Aliskiren

3. Cgp 060536b

4. Cgp-060536b

5. Cgp060536b

6. Rasilez

7. Spp100

8. Tekturna

2.3.2 Depositor-Supplied Synonyms

1. 173334-58-2

2. Tekturna

3. Aliskiren Fumarate

4. Aliskiren (hemifumarate)

5. Enviage

6. Riprazo

7. Sprimeo

8. Spp-100b

9. Chebi:53777

10. C8a0p8g029

11. Nsc-759185

12. Cgp 60536

13. Aliskirenfumarate

14. (2s,4s,5s,7s)-5-amino-n-(3-amino-2,2-dimethyl-3-oxopropyl)-4-hydroxy-7-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-8-methyl-2-propan-2-ylnonanamide;(e)-but-2-enedioic Acid

15. Cgp60536b

16. Bis(2s,4s,5s,7s)-5-amino-n-(3-amino-2,2-dimethyl-3-oxopropyl)-4-hydroxy-7-(4-methoxy-3-(3-methoxypropoxy)benzyl)-8-methyl-2-(1-methylethyl)nonanamide) (2e)-but-2-enedioate

17. Aliskiren Fumarate [usan]

18. Unii-c8a0p8g029

19. Aliskiren Fumarate [usan:jan]

20. Tekturna (tn)

21. Cgp-60536

22. Aliskiren Hemifumarate- Bio-x

23. Schembl187762

24. Aliskiren (as Fumarate)

25. Aliskiren Fumarate (jan/usan)

26. Aliskiren Fumarate [jan]

27. Chembl3545059

28. Cgp-60536b

29. Aliskiren Fumarate [mart.]

30. Aliskiren Hemifumarate [mi]

31. Aliskiren Fumarate [who-dd]

32. Mfcd10566724

33. S2199

34. Aliskiren Hemifumarate [vandf]

35. Akos015896419

36. Ccg-270658

37. Cs-0729

38. Ks-1395

39. Nsc 759185

40. S12129

41. (2s,4s,5s,7s)-5-amino-n-(3-amino-2,2-dimethyl-3-oxopropyl)-4-hydroxy-2-isopropyl-7-(4-methoxy-3-(3-methoxypropoxy)benzyl)-8-methylnonanamide Hemifumarate

42. Ba164146

43. Hy-12177

44. Aliskiren Hemifumarate [orange Book]

45. Sw222231-1

46. D06412

47. Rasitrio Component Aliskiren Hemifumarate

48. Tekamlo Component Aliskiren Hemifumarate

49. Valturna Component Aliskiren Hemifumarate

50. Amturnide Component Aliskiren Hemifumarate

51. Rasilamlo Component Aliskiren Hemifumarate

52. Aliskiren Hemifumarate Component Of Rasitrio

53. Aliskiren Hemifumarate Component Of Tekamlo

54. Aliskiren Hemifumarate Component Of Valturna

55. Raprazo-hct Component Aliskiren Hemifumarate

56. Rasilez-hct Component Aliskiren Hemifumarate

57. Sprimeo-hct Component Aliskiren Hemifumarate

58. Aliskiren Hemifumarate Component Of Amturnide

59. Aliskiren Hemifumarate Component Of Rasilamlo

60. Tekturna Hct Component Aliskiren Hemifumarate

61. Aliskiren Hemifumarate Component Of Raprazo-hct

62. Aliskiren Hemifumarate Component Of Rasilez-hct

63. Aliskiren Hemifumarate Component Of Sprimeo-hct

64. Q27124205

65. Aliskiren Hemifumarate Component Of Tekturna Hct

66. (?s,?s,?s,?s)-?-amino-n-(3-amino-2,2-dimethyl-3-oxopropyl)-?-hydroxy-4-methoxy-3-(3-methoxypropoxy)-?,?-bis(1-methylethyl)benzeneoctanamide Hemifumarate

67. 5-amino-n-(3-amino-2,2-dime-3-oxoprop)-4-oh-2-isoprop-7-[4-meo-3-(3-meo-propoxy)benzyl]-8-methylnonanamide Hemifumarate

68. Benzeneoctanamide, Delta-amino-n-(3-amino-2,2-dimethyl-3-oxopropyl)-gamma-hydroxy-4-methoxy-3-(3-methoxypropoxy)-alpha,zeta-bis(1-methylethyl)-, (alphas,gammas,deltas,zetas)-, (2e)-2-butenedioate (2:1) (salt)

69. Bis((2s,4s,5s,7s)-5-amino-n-(3-amino-2,2-dimethyl-3-oxopropyl)-4-hydroxy-2-isopropyl-7-(4-methoxy-3-(3-methoxypropoxy)benzyl)-8-methylnonanamide) Fumarate

70. Bis{(2s,4s,5s,7s)-5-amino-n-(3-amino-2,2-dimethyl-3-oxopropyl)-4-hydroxy-7-[4-methoxy-3-(3-methoxypropoxy)benzyl]-8-methyl-2-(propan-2-yl)nonanamide} (2e)-but-2-enedioate

2.4 Create Date
2006-07-28
3 Chemical and Physical Properties
Molecular Weight 1219.6 g/mol
Molecular Formula C64H110N6O16
Hydrogen Bond Donor Count10
Hydrogen Bond Acceptor Count18
Rotatable Bond Count40
Exact Mass1218.79783144 g/mol
Monoisotopic Mass1218.79783144 g/mol
Topological Polar Surface Area367 Ų
Heavy Atom Count86
Formal Charge0
Complexity836
Isotope Atom Count0
Defined Atom Stereocenter Count8
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count1
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count3
4 Drug and Medication Information
4.1 Drug Information
1 of 2  
Drug NameTekturna
PubMed HealthAliskiren (By mouth)
Drug ClassesAntihypertensive
Drug LabelTekturna contains aliskiren hemifumarate, a renin inhibitor, that is provided as tablets for oral administration. Aliskiren hemifumarate is chemically described as (2S,4S,5S,7S)-N-(2-carbamoyl-2-methylpropyl)-5-amino-4-hydroxy-2,7-diisopropyl-8-[4-me...
Active IngredientAliskiren hemifumarate
Dosage FormTablet
RouteOral
Strengtheq 150mg base; eq 300mg base
Market StatusPrescription
CompanyNovartis

2 of 2  
Drug NameTekturna
PubMed HealthAliskiren (By mouth)
Drug ClassesAntihypertensive
Drug LabelTekturna contains aliskiren hemifumarate, a renin inhibitor, that is provided as tablets for oral administration. Aliskiren hemifumarate is chemically described as (2S,4S,5S,7S)-N-(2-carbamoyl-2-methylpropyl)-5-amino-4-hydroxy-2,7-diisopropyl-8-[4-me...
Active IngredientAliskiren hemifumarate
Dosage FormTablet
RouteOral
Strengtheq 150mg base; eq 300mg base
Market StatusPrescription
CompanyNovartis

4.2 Drug Indication

Treatment of essential hypertension.


Treatment of essential hypertension.


Treatment of essential hypertension


Treatment of essential hypertension


5 Pharmacology and Biochemistry
5.1 FDA Pharmacological Classification
5.1.1 Pharmacological Classes
Renin Inhibitors [MoA]; Renin Inhibitor [EPC]
5.2 ATC Code

C09XA02


C09XA02


C09XA02


C09XA02


FDA Orange Book

read-more
read-more

01

NODEN PHARMA

Ireland
Pharmatech Expo 2025
Not Confirmed
arrow

NODEN PHARMA

Ireland
arrow
Pharmatech Expo 2025
Not Confirmed

ALISKIREN HEMIFUMARATE

Brand Name : TEKTURNA

Dosage Form : TABLET;ORAL

Dosage Strength : EQ 300MG BASE

Approval Date : 2007-03-05

Application Number : 21985

RX/OTC/DISCN : RX

RLD : Yes

TE Code : AB

blank

02

NODEN PHARMA

Ireland
Pharmatech Expo 2025
Not Confirmed
arrow

NODEN PHARMA

Ireland
arrow
Pharmatech Expo 2025
Not Confirmed

ALISKIREN HEMIFUMARATE; HYDROCHLOROTHIAZIDE

Brand Name : TEKTURNA HCT

Dosage Form : TABLET;ORAL

Dosage Strength : EQ 150MG BASE;12.5MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

Approval Date : 2008-01-18

Application Number : 22107

RX/OTC/DISCN : DISCN

RLD : Yes

TE Code :

blank

03

NODEN PHARMA

Ireland
Pharmatech Expo 2025
Not Confirmed
arrow

NODEN PHARMA

Ireland
arrow
Pharmatech Expo 2025
Not Confirmed

ALISKIREN HEMIFUMARATE; HYDROCHLOROTHIAZIDE

Brand Name : TEKTURNA HCT

Dosage Form : TABLET;ORAL

Dosage Strength : EQ 150MG BASE;25MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

Approval Date : 2008-01-18

Application Number : 22107

RX/OTC/DISCN : DISCN

RLD : Yes

TE Code :

blank

04

NODEN PHARMA

Ireland
Pharmatech Expo 2025
Not Confirmed
arrow

NODEN PHARMA

Ireland
arrow
Pharmatech Expo 2025
Not Confirmed

ALISKIREN HEMIFUMARATE; HYDROCHLOROTHIAZIDE

Brand Name : TEKTURNA HCT

Dosage Form : TABLET;ORAL

Dosage Strength : EQ 300MG BASE;12.5MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

Approval Date : 2008-01-18

Application Number : 22107

RX/OTC/DISCN : DISCN

RLD : Yes

TE Code :

blank

05

NODEN PHARMA

Ireland
Pharmatech Expo 2025
Not Confirmed
arrow

NODEN PHARMA

Ireland
arrow
Pharmatech Expo 2025
Not Confirmed

ALISKIREN HEMIFUMARATE

Brand Name : TEKTURNA

Dosage Form : CAPSULE, PELLET;ORAL

Dosage Strength : EQ 37.5MG BASE

Approval Date : 2017-11-14

Application Number : 210709

RX/OTC/DISCN : DISCN

RLD : Yes

TE Code :

blank

06

NOVARTIS

Switzerland
Pharmatech Expo 2025
Not Confirmed
arrow

NOVARTIS

Switzerland
arrow
Pharmatech Expo 2025
Not Confirmed

ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE

Brand Name : TEKAMLO

Dosage Form : TABLET;ORAL

Dosage Strength : EQ 150MG BASE;EQ 10MG BASE

Approval Date : 2010-08-26

Application Number : 22545

RX/OTC/DISCN : DISCN

RLD : No

TE Code :

blank

07

NOVARTIS

Switzerland
Pharmatech Expo 2025
Not Confirmed
arrow

NOVARTIS

Switzerland
arrow
Pharmatech Expo 2025
Not Confirmed

ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE

Brand Name : TEKAMLO

Dosage Form : TABLET;ORAL

Dosage Strength : EQ 300MG BASE;EQ 5MG BASE

Approval Date : 2010-08-26

Application Number : 22545

RX/OTC/DISCN : DISCN

RLD : No

TE Code :

blank

08

NOVARTIS

Switzerland
Pharmatech Expo 2025
Not Confirmed
arrow

NOVARTIS

Switzerland
arrow
Pharmatech Expo 2025
Not Confirmed

ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE

Brand Name : TEKAMLO

Dosage Form : TABLET;ORAL

Dosage Strength : EQ 300MG BASE;EQ 10MG BASE

Approval Date : 2010-08-26

Application Number : 22545

RX/OTC/DISCN : DISCN

RLD : No

TE Code :

blank

09

NOVARTIS

Switzerland
Pharmatech Expo 2025
Not Confirmed
arrow

NOVARTIS

Switzerland
arrow
Pharmatech Expo 2025
Not Confirmed

ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE

Brand Name : AMTURNIDE

Dosage Form : TABLET;ORAL

Dosage Strength : EQ 150MG BASE;EQ 5MG BASE;12.5MG

Approval Date : 2010-12-21

Application Number : 200045

RX/OTC/DISCN : DISCN

RLD : No

TE Code :

blank

10

ENDO OPERATIONS

Country
Pharmatech Expo 2025
Not Confirmed
arrow

ENDO OPERATIONS

Country
arrow
Pharmatech Expo 2025
Not Confirmed

ALISKIREN HEMIFUMARATE

Brand Name : ALISKIREN HEMIFUMARATE

Dosage Form : TABLET;ORAL

Dosage Strength : EQ 150MG BASE

Approval Date : 2019-03-22

Application Number : 206665

RX/OTC/DISCN : RX

RLD : No

TE Code : AB

blank
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Europe

read-more
read-more

01

Future Health Pharma GmbH

Country
Pharmatech Expo 2025
Not Confirmed
arrow

Future Health Pharma GmbH

Country
arrow
Pharmatech Expo 2025
Not Confirmed

Aliskirenum

Brand Name : Rasilez

Dosage Form : Filmtabl

Dosage Strength : 150mg

Packaging :

Approval Date :

Application Number :

Regulatory Info :

Registration Country : Switzerland

blank

02

Future Health Pharma GmbH

Country
Pharmatech Expo 2025
Not Confirmed
arrow

Future Health Pharma GmbH

Country
arrow
Pharmatech Expo 2025
Not Confirmed

Aliskirenum

Brand Name : Rasilez

Dosage Form : Filmtabl

Dosage Strength : 150mg

Packaging :

Approval Date :

Application Number :

Regulatory Info :

Registration Country : Switzerland

blank

03

Future Health Pharma GmbH

Country
Pharmatech Expo 2025
Not Confirmed
arrow

Future Health Pharma GmbH

Country
arrow
Pharmatech Expo 2025
Not Confirmed

Aliskirenum

Brand Name : Rasilez

Dosage Form : Filmtabl

Dosage Strength : 300mg

Packaging :

Approval Date :

Application Number :

Regulatory Info :

Registration Country : Switzerland

blank

04

Future Health Pharma GmbH

Country
Pharmatech Expo 2025
Not Confirmed
arrow

Future Health Pharma GmbH

Country
arrow
Pharmatech Expo 2025
Not Confirmed

Aliskirenum

Brand Name : Rasilez

Dosage Form : Filmtabl

Dosage Strength : 300mg

Packaging :

Approval Date :

Application Number :

Regulatory Info :

Registration Country : Switzerland

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

DRUG PRODUCT COMPOSITIONS

Do you need Business Intel? Ask us

DOSAGE - TABLET;ORAL - EQ 150MG BASE

USFDA APPLICATION NUMBER - 21985

read-more

DOSAGE - TABLET;ORAL - EQ 300MG BASE

USFDA APPLICATION NUMBER - 21985

read-more

DOSAGE - TABLET;ORAL - EQ 150MG BASE;12.5MG *...DOSAGE - TABLET;ORAL - EQ 150MG BASE;12.5MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

USFDA APPLICATION NUMBER - 22107

read-more

DOSAGE - TABLET;ORAL - EQ 150MG BASE;25MG **F...DOSAGE - TABLET;ORAL - EQ 150MG BASE;25MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

USFDA APPLICATION NUMBER - 22107

read-more

DOSAGE - TABLET;ORAL - EQ 300MG BASE;12.5MG *...DOSAGE - TABLET;ORAL - EQ 300MG BASE;12.5MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

USFDA APPLICATION NUMBER - 22107

read-more

DOSAGE - TABLET;ORAL - EQ 300MG BASE;25MG **F...DOSAGE - TABLET;ORAL - EQ 300MG BASE;25MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

USFDA APPLICATION NUMBER - 22107

read-more

Related Excipient Companies

Upload your portfolio for free, ask us

Excipients by Applications

Click here to find the perfect excipient manufacturers by their capabilities

Coating Systems & Additives

read-more
read-more

Fillers, Diluents & Binders

read-more
read-more

Controlled & Modified Release

read-more
read-more

Direct Compression

read-more
read-more

Thickeners and Stabilizers

read-more
read-more

Disintegrants & Superdisintegrants

read-more
read-more

Granulation

read-more
read-more

Solubilizers

read-more
read-more

Lubricants & Glidants

read-more
read-more

Co-Processed Excipients

read-more
read-more

Film Formers & Plasticizers

read-more
read-more

Topical

read-more
read-more

Chewable & Orodispersible Aids

read-more
read-more

Coloring Agents

read-more
read-more

Empty Capsules

read-more
read-more

Taste Masking

read-more
read-more

Emulsifying Agents

read-more
read-more

Parenteral

read-more
read-more

Vegetarian Capsules

read-more
read-more

API Stability Enhancers

read-more
read-more

Rheology Modifiers

read-more
read-more

Digital Content read-more

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

Global Sales Information

Do you need Business Intel? Ask us

Market Place

Do you need sourcing support? Ask us

Patents & EXCLUSIVITIES

Check the patents & exclusivity for this product

ABOUT THIS PAGE

ALISKIREN HEMIFUMARATE Manufacturers

A ALISKIREN HEMIFUMARATE manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of ALISKIREN HEMIFUMARATE, including repackagers and relabelers. The FDA regulates ALISKIREN HEMIFUMARATE manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. ALISKIREN HEMIFUMARATE API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.

click here to find a list of ALISKIREN HEMIFUMARATE manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.

ALISKIREN HEMIFUMARATE Suppliers

A ALISKIREN HEMIFUMARATE supplier is an individual or a company that provides ALISKIREN HEMIFUMARATE active pharmaceutical ingredient (API) or ALISKIREN HEMIFUMARATE finished formulations upon request. The ALISKIREN HEMIFUMARATE suppliers may include ALISKIREN HEMIFUMARATE API manufacturers, exporters, distributors and traders.

click here to find a list of ALISKIREN HEMIFUMARATE suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.

ALISKIREN HEMIFUMARATE USDMF

A ALISKIREN HEMIFUMARATE DMF (Drug Master File) is a document detailing the whole manufacturing process of ALISKIREN HEMIFUMARATE active pharmaceutical ingredient (API) in detail. Different forms of ALISKIREN HEMIFUMARATE DMFs exist exist since differing nations have different regulations, such as ALISKIREN HEMIFUMARATE USDMF, ASMF (EDMF), JDMF, CDMF, etc.

A ALISKIREN HEMIFUMARATE DMF submitted to regulatory agencies in the US is known as a USDMF. ALISKIREN HEMIFUMARATE USDMF includes data on ALISKIREN HEMIFUMARATE's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The ALISKIREN HEMIFUMARATE USDMF is kept confidential to protect the manufacturer’s intellectual property.

click here to find a list of ALISKIREN HEMIFUMARATE suppliers with USDMF on PharmaCompass.

ALISKIREN HEMIFUMARATE WC

A ALISKIREN HEMIFUMARATE written confirmation (ALISKIREN HEMIFUMARATE WC) is an official document issued by a regulatory agency to a ALISKIREN HEMIFUMARATE manufacturer, verifying that the manufacturing facility of a ALISKIREN HEMIFUMARATE active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting ALISKIREN HEMIFUMARATE APIs or ALISKIREN HEMIFUMARATE finished pharmaceutical products to another nation, regulatory agencies frequently require a ALISKIREN HEMIFUMARATE WC (written confirmation) as part of the regulatory process.

click here to find a list of ALISKIREN HEMIFUMARATE suppliers with Written Confirmation (WC) on PharmaCompass.

ALISKIREN HEMIFUMARATE NDC

National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing ALISKIREN HEMIFUMARATE as an active pharmaceutical ingredient (API).

Finished drug products

The FDA updates the NDC directory daily. The NDC numbers for ALISKIREN HEMIFUMARATE API and other APIs are published in this directory by the FDA.

Unfinished drugs

The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.

Pharmaceutical companies that manufacture ALISKIREN HEMIFUMARATE as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.

Compounded drug products

The NDC directory also contains data on finished compounded human drug products that contain ALISKIREN HEMIFUMARATE and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a ALISKIREN HEMIFUMARATE NDC to their finished compounded human drug products, they may choose to do so.

click here to find a list of ALISKIREN HEMIFUMARATE suppliers with NDC on PharmaCompass.

ALISKIREN HEMIFUMARATE GMP

ALISKIREN HEMIFUMARATE Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.

GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).

PharmaCompass offers a list of ALISKIREN HEMIFUMARATE GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right ALISKIREN HEMIFUMARATE GMP manufacturer or ALISKIREN HEMIFUMARATE GMP API supplier for your needs.

ALISKIREN HEMIFUMARATE CoA

A ALISKIREN HEMIFUMARATE CoA (Certificate of Analysis) is a formal document that attests to ALISKIREN HEMIFUMARATE's compliance with ALISKIREN HEMIFUMARATE specifications and serves as a tool for batch-level quality control.

ALISKIREN HEMIFUMARATE CoA mostly includes findings from lab analyses of a specific batch. For each ALISKIREN HEMIFUMARATE CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.

ALISKIREN HEMIFUMARATE may be tested according to a variety of international standards, such as European Pharmacopoeia (ALISKIREN HEMIFUMARATE EP), ALISKIREN HEMIFUMARATE JP (Japanese Pharmacopeia) and the US Pharmacopoeia (ALISKIREN HEMIFUMARATE USP).

Inform the supplier about your product requirements, specifying if you need a product with particular monograph like EP (Ph. Eur.), USP, JP, BP, or any other quality. In addition, clarify whether you need hydrochloride (HCl), anhydricum, base, micronisatum or a specific level of purity. To find reputable suppliers, utilize the filters and select those certified by GMP, FDA, or any other certification as per your requirement.
For your convenience, we have listed synonyms and CAS numbers to help you find the best supplier. The use of synonyms and CAS numbers can be helpful in identifying potential suppliers, but it is crucial to note that they might not always indicate the exact same product. It is important to confirm the product details with the supplier before making a purchase to ensure that it meets your requirements.
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty